Smoke and COVID-19 case fatality ratios during California wildfires

Recent evidence has shown an association between wildfire smoke and COVID-19 cases and deaths. The San Francisco Bay Area, in California (USA), experienced two major concurrent public health threats in 2020: the COVID-19 pandemic and dense smoke emitted by wildfires. This provides a unprecedented context to unravel the role of acute air pollution exposure on COVID-19 severity. A smoke product provided by the National Oceanic and Atmospheric Association Hazard Mapping System was used to identify counties exposed to heavy smoke in summer and fall of 2020. Daily COVID-19 cases and deaths for the United States were downloaded at the County-level from the CDC COVID Data Tracker. Synthetic control methods were used to estimate the causal effect of the wildfire smoke on daily COVID-19 case fatality ratios (CFRs), adjusting for population mobility. Evidence of an impact of wildfire smoke on COVID-19 CFRs was observed, with precise estimates in Alameda and San Francisco. Up to 58 (95% CI: 29, 87) additional deaths for every 1000 COVID-19 incident daily cases attributable to wildfire smoke was estimated in Alameda in early September. Findings indicated that extreme weather events such as wildfires smoke can drive increased vulnerability to infectious diseases, highlighting the need to further study these colliding crises. Understanding the environmental drivers of COVID-19 mortality can be used to protect vulnerable populations from these potentially concomitant public health threats.

[Strategy for the practice of digestive and oncologic surgery in COVID-19 epidemic situation]. / Stratégie pour la pratique de la chirurgie digestive et oncologique en situation d'épidémie de COVID-19.

The COVID-19 pandemic is changing the organization of healthcare and has a direct impact on digestive surgery. Healthcare priorities and circuits are being modified. Emergency surgery is still a priority. Functional surgery is to be deferred. Laparoscopic surgery must follow strict rules so as not to expose healthcare professionals (HCPs) to added risk. The question looms large in cancer surgery - go ahead or defer? There is probably an added risk due to the pandemic that must be balanced against the risk incurred by deferring surgery. For each type of cancer - colon, pancreas, oesogastric, hepatocellular carcinoma - morbidity and mortality rates are stated and compared with the oncological risk incurred by deferring surgery and/or the tumour doubling time. Strategies can be proposed based on this comparison. For colonic cancers T1-2, N0, it is advisable to defer surgery. For advanced colonic lesions, it seems judicious to undertake neoadjuvant chemotherapy and then wait. For rectal cancers T3-4 and /or N+, chemoradiotherapy is indicated, short radiotherapy must be discussed (followed by a waiting period) to reduce time of exposure in the hospital and to prevent infections. Most complex surgery with high morbidity and mortality - oesogastric, hepatic or pancreatic - is most often best deferred.

Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic.

The Covid-19 pandemic is changing the organization of healthcare and has a direct impact on digestive surgery. Healthcare priorities and circuits are being modified. Emergency surgery is still a priority. Functional surgery is to be deferred. Laparoscopic surgery must follow strict rules so as not to expose healthcare professionals (HCPs) to added risk. The question looms large in cancer surgery-go ahead or defer? There is probably an added risk due to the pandemic that must be balanced against the risk incurred by deferring surgery. For each type of cancer-colon, pancreas, oesogastric, hepatocellular carcinoma-morbidity and mortality rates are stated and compared with the oncological risk incurred by deferring surgery and/or the tumour doubling time. Strategies can be proposed based on this comparison. For colonic cancers T1-2, N0, it is advisable to defer surgery. For advanced colonic lesions, it seems judicious to undertake neoadjuvant chemotherapy and then wait. For rectal cancers T3-4 and/or N+, chemoradiotherapy is indicated, short radiotherapy must be discussed (followed by a waiting period) to reduce time of exposure in the hospital and to prevent infections. Most complex surgery with high morbidity and mortality-oesogastric, hepatic or pancreatic-is most often best deferred.